Pediatric vaccines work as a protective shield for infants, children and adolescents (age ranging from 0-18 years) against various fatal diseases such as influenza, diphtheria, hepatitis, meningococcal and pneumococcal diseases etc.
The global pediatric vaccine market was valued at USD 24 Billion in 2015 and is anticipated to exhibit a robust compound annual growth rate (CAGR) of 10.6% over the forecast period. Regionally, the global pediatric vaccine market is segmented into North America, Latin America, Western and Eastern Europe, Asia-Pacific and Rest of World. Asia-Pacific is projected to witness the highest growth rate in pediatric vaccines market in coming 5-6 years.
On the basis of technology, the global paediatric market is segmented into synthetic vaccines, dendritic cells vaccines, toxoid vaccines, live attenuated vaccines, inactivated vaccines, subunit vaccines and recombinant vector vaccines.
Based on disease the global paediatric market is segmented into cancer, Hepatitis A, Hepatitis B, Influenza, Polio, Rotavirus, Tetanus, allergy, infectious disease and other diseases.
The study further analysis the Y-O-Y Growth, demand & supply and forecast future opportunity in North America (United States, Canada), Latin America (Brazil, Mexico, Argentina, Rest of LATAM), Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX (Belgium, Netherlands, Luxembourg), NORDIC (Norway, Denmark, Sweden, Finland), Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa).
Growth Drivers and challenges
Expanding government and private spending on development of pediatric and other vaccines is a major factor which is believed to foster the growth of global paediatric market in coming 5-6 years.
However, limited or no access to healthcare services in developing/under-developed countries, low healthcare spending, and lower pediatric vaccination coverage etc. are some of the challenges which might hamper the growth of global paediatric vaccines market in future.
Market Size and Forecast
North America holds the top rank in pediatric vaccines market in the world. The pediatric vaccines market in North America is sparked by higher spending by the Federal government on healthcare industry. The U.S. and Canada are two major markets of pediatric vaccines in North America.
Europe pediatric vaccines market is also propelled by larger government spending on development of medical and pharmaceutical industry. The market in major European countries such as Germany, Italy, France, Spain and U.K. is boosted from the funding allotted by public healthcare services such as NHS (Nation Healthcare Service).CLICK TO DOWNLOAD FREE SAMPLE REPORT
Asia-Pacific paediatric vaccines market is expected to get escalated by increasing initiatives of World Health organisation (WHO) in countries such as India, China and Japan. In addition to that, Asia-Pacific pediatric market is also likely to get fostered from strengthening economic growth of major Asian countries in future.
The global pediatric vaccines market includes some of the top players such as Pfize, Merck, Sanofi Pasteur, Sinovac Biotech, Bio Med, Valeant Pharmaceuticals, Dynavax Technologies etc.
Scope and Context
Overview of the Parent Market
Market Size and Growth
Supply & Demand Risk
Porter’s Five Force Model
Geographical Economic Activity
Key Players (respective SWOT Analysis) and their Strategies and Product Portfolio
Recent Trends and Developments
Industry Growth Drivers and Challenges
Key Information for Players to establish themselves in current dynamic environment
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization
Great focus on accuracy and quality of the research
(U.S.) - +1 646 586 9123
(Canada) - +1 437 889 3230
(U.K.) - +44 203 608 5919
(India) - + 91 120 660 5495